Cargando…

Phospho-Tau and Chromatin Landscapes in Early and Late Alzheimer’s Disease

Cellular identity is determined through complex patterns of gene expression. Chromatin, the dynamic structure containing genetic information, is regulated through epigenetic modulators, mainly by the histone code. One of the main challenges for the cell is maintaining functionality and identity, des...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, Laura, Niño, Sandra A., Guerrero, Carmen, Jiménez-Capdeville, María E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509045/ https://www.ncbi.nlm.nih.gov/pubmed/34638632 http://dx.doi.org/10.3390/ijms221910283

Ejemplares similares

Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
por: Sanchez-Mejias, Elisabeth, et al.
Publicado: (2016)

Pathological Nuclear Hallmarks in Dentate Granule Cells of Alzheimer’s Patients: A Biphasic Regulation of Neurogenesis
por: Gil, Laura, et al.
Publicado: (2022)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Phospho-Tau and Cognitive Decline in Alzheimer's Disease. Commentary: Tau in physiology and pathology
por: DeFelipe, Javier
Publicado: (2016)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Perinuclear Lamin A and Nucleoplasmic Lamin B2 Characterize Two Types of Hippocampal Neurons through Alzheimer’s Disease Progression
por: Gil, Laura, et al.
Publicado: (2020)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Phospho-Tau Changes in the Human CA1 During Alzheimer’s Disease Progression
por: Regalado-Reyes, Mamen, et al.
Publicado: (2019)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
por: Barthélemy, Nicolas R., et al.
Publicado: (2022)

Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer’s disease and PART
por: Kaufman, Sarah K., et al.
Publicado: (2018)

The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimer’s disease
por: Merino-Serrais, Paula, et al.
Publicado: (2013)

Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study
por: Plowey, Edward D., et al.
Publicado: (2016)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
por: Cruchaga, Carlos, et al.
Publicado: (2010)

Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics
por: Metaxas, Athanasios, et al.
Publicado: (2016)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains
por: Barrera, Julio, et al.
Publicado: (2021)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer’s Disease
por: Bencze, János, et al.
Publicado: (2020)

Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons
por: Hoe, Hyang-Sook, et al.
Publicado: (2006)

Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy
por: Kimura, Taeko, et al.
Publicado: (2018)

The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder
por: SARAÇOĞLU, Hatice, et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
por: Sankaranarayanan, Sethu, et al.
Publicado: (2015)

Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease
por: Lee, Wha Jin, et al.
Publicado: (2022)

Ante‐ and postmortem tau in autosomal dominant and late‐onset Alzheimer’s disease
por: Chen, Charles D., et al.
Publicado: (2020)

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies
por: d’Abramo, Cristina, et al.
Publicado: (2015)

β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline
por: Hammond, Tyler C., et al.
Publicado: (2020)

Association of Subcortical Structural Shapes With Tau, Amyloid, and Cortical Atrophy in Early-Onset and Late-Onset Alzheimer’s Disease
por: Lee, Eun-Chong, et al.
Publicado: (2020)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gnmmsuh03caog6lujmcbl5gluv